Literature DB >> 8642667

A recombinant adenovirus expressing an Epstein-Barr virus (EBV) target antigen can selectively reactivate rare components of EBV cytotoxic T-lymphocyte memory in vitro.

S M Morgan1, G W Wilkinson, E Floettmann, N Blake, A B Rickinson.   

Abstract

While the bulk of a virus-induced cytotoxic T-lymphocyte (CTL) response may focus on a few immunodominant viral antigens, in certain tumor virus systems the detectability of clones recognizing other, subdominant antigens can assume particular importance. By using the human CTL response to Epstein-Barr virus (EBV) as a model system, here we show that even rare components of virus-specific memory can be selectively reactivated in vitro when the relevant target antigen is expressed in autologous stimulator cells from a recombinant adenovirus (RAd) vector. We generated a replication-deficient adenovirus, RAd-E3C, which in skin fibroblast cultures expressed the EBV nuclear antigen EBNA3C at a 10- to 100-fold-higher level than that naturally present in EBV-transformed lymphoblastoid cell lines (LCLs). Initial experiments with a donor whose polyclonal CTL response to LCL stimulation contained a strong EBNA3C-specific component showed that these CTLs could be efficiently reactivated by in vitro stimulation either with RAd-E3C-infected fibroblasts or with RAd-E3C-infected peripheral blood mononuclear cells. Then we studied donors whose responses to LCL stimulation contained little if any detectable EBNA3C reactivity but were dominated by clones recognizing other EBV target antigens; in vitro stimulation with RAd-E3C-infected peripheral blood mononuclear cells selectively reactivated EBNA3C-specific CTL clones from these individuals, with the epitope specificities of responses subsequently identified at the peptide level. This RAd-based approach could be applied more generally to screen for human CTL responses against any candidate target antigen expressed by tumor cells.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8642667      PMCID: PMC190082     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  40 in total

1.  An Epstein-Barr virus-specific cytotoxic T-cell epitope present on A- and B-type transformants.

Authors:  S R Burrows; I S Misko; T B Sculley; C Schmidt; D J Moss
Journal:  J Virol       Date:  1990-08       Impact factor: 5.103

2.  Identification of an immunodominant cytotoxic T-lymphocyte recognition site in glycoprotein B of herpes simplex virus by using recombinant adenovirus vectors and synthetic peptides.

Authors:  T Hanke; F L Graham; K L Rosenthal; D C Johnson
Journal:  J Virol       Date:  1991-03       Impact factor: 5.103

3.  Precipitation of the Epstein-Barr virus protein EBNA 2 by an EBNA 3c-specific monoclonal antibody.

Authors:  M J Maunders; L Petti; M Rowe
Journal:  J Gen Virol       Date:  1994-04       Impact factor: 3.891

Review 4.  Antigen recognition by class I-restricted T lymphocytes.

Authors:  A Townsend; H Bodmer
Journal:  Annu Rev Immunol       Date:  1989       Impact factor: 28.527

5.  Cytotoxic T-cell clones discriminate between A- and B-type Epstein-Barr virus transformants.

Authors:  D J Moss; I S Misko; S R Burrows; K Burman; R McCarthy; T B Sculley
Journal:  Nature       Date:  1988-02-25       Impact factor: 49.962

6.  A simple technique for the rescue of early region I mutations into infectious human adenovirus type 5.

Authors:  W J McGrory; D S Bautista; F L Graham
Journal:  Virology       Date:  1988-04       Impact factor: 3.616

7.  Cloning of the herpes simplex virus ICP4 gene in an adenovirus vector: effects on adenovirus gene expression and replication.

Authors:  R Spessot; K Inchley; T M Hupel; S Bacchetti
Journal:  Virology       Date:  1989-02       Impact factor: 3.616

Review 8.  Human papillomaviruses in the pathogenesis of anogenital cancer.

Authors:  H zur Hausen
Journal:  Virology       Date:  1991-09       Impact factor: 3.616

9.  Murine cytotoxic T lymphocyte recognition of individual influenza virus proteins. High frequency of nonresponder MHC class I alleles.

Authors:  J R Bennink; J W Yewdell
Journal:  J Exp Med       Date:  1988-11-01       Impact factor: 14.307

10.  Human cytomegalovirus-specific cytotoxic T cells. Relative frequency of stage-specific CTL recognizing the 72-kD immediate early protein and glycoprotein B expressed by recombinant vaccinia viruses.

Authors:  L K Borysiewicz; J K Hickling; S Graham; J Sinclair; M P Cranage; G L Smith; J G Sissons
Journal:  J Exp Med       Date:  1988-09-01       Impact factor: 14.307

View more
  5 in total

1.  Biophysical and mutational analysis of the putative bZIP domain of Epstein-Barr virus EBNA 3C.

Authors:  Michelle J West; Helen M Webb; Alison J Sinclair; Derek N Woolfson
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

2.  Immediate-early transactivator Rta of Epstein-Barr virus (EBV) shows multiple epitopes recognized by EBV-specific cytotoxic T lymphocytes.

Authors:  S Pepperl; G Benninger-Döring; S Modrow; H Wolf; W Jilg
Journal:  J Virol       Date:  1998-11       Impact factor: 5.103

3.  Dendritic cells transduced with an adenovirus vector encoding Epstein-Barr virus latent membrane protein 2B: a new modality for vaccination.

Authors:  E Ranieri; W Herr; A Gambotto; W Olson; D Rowe; P D Robbins; L S Kierstead; S C Watkins; L Gesualdo; W J Storkus
Journal:  J Virol       Date:  1999-12       Impact factor: 5.103

4.  Simultaneous assessment of cytotoxic T lymphocyte responses against multiple viral infections by combined usage of optimal epitope matrices, anti- CD3 mAb T-cell expansion and "RecycleSpot"

Authors:  Florian K Bihl; Elisabetta Loggi; John V Chisholm; Hannah S Hewitt; Leah M Henry; Caitlyn Linde; Todd J Suscovich; Johnson T Wong; Nicole Frahm; Pietro Andreone; Christian Brander
Journal:  J Transl Med       Date:  2005-05-11       Impact factor: 5.531

5.  Identification of a polymorphic gene, BCL2A1, encoding two novel hematopoietic lineage-specific minor histocompatibility antigens.

Authors:  Yoshiki Akatsuka; Tetsuya Nishida; Eisei Kondo; Mikinori Miyazaki; Hirohumi Taji; Hiroatsu Iida; Kunio Tsujimura; Makoto Yazaki; Tomoki Naoe; Yasuo Morishima; Yoshihisa Kodera; Kiyotaka Kuzushima; Toshitada Takahashi
Journal:  J Exp Med       Date:  2003-05-27       Impact factor: 14.307

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.